Leukotriene B4, an arachidonic acid metabolite, is a potent chemotactic agent, and is thought to be an important mediator of inflammation. To investigate the role of this compound as a mediator of inflammation in inflammatory bowel disease, arachidonic acid was incubated with ionophore and colonic mucosa from patients with inflammatory bowel disease and from normal subjects. Mucosa from patients with inflammatory bowel disease converted 2.17% of exogenous arachidonate to leukotriene B4; mucosa from normal subjects converted 0.37%. The production of leukotriene was blocked by sulfasalazine. To determine if inflammatory bowel mucosa contained endogenous leukotriene B4 , lipid extracts were analyzed by high pressure liquid chromatography. Mucosa from patients with inflammatory bowel disease contained 254 ng of leukotriene B4 per gram and mucosa from normal subjects contained <5 ng of leukotriene B4 per gram. The presence of significant amounts of leukotriene B4 in colonic mucosa in patients with inflammatory bowel disease, combined with the known biologic effects of leukotriene B4, suggests that it may be an important mediator of inflammation in inflammatory bowel disease. 

The Journal uses Editorial Manager System for a qualitative and prompt review process. Review processing is performed by the editorial board members of Journal of Pharmaceutical Sciences & Emerging Drugs or relevant experts from other universities or institutes. Minimum two independent reviewer’s approval followed by editor approval is required for the acceptance of any citable manuscript. Authors may submit manuscripts online / through mail id: editor.rrg@peerjournal.org and track their progress through the online tracking system, hopefully to publication.

Best Regards,
Editorial Manager
Research and Reports in Gastroentrology
Email: gasroentero@eclinicalsci.com